Poster: Primary Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro

The RepliGut SOT 2023 poster, presented at the 2023 SOT meeting, features collaborators from Janssen Pharmaceuticals describing their use of the RepliGut® Planar Platform  to distinguish between compounds with different potencies for the JNJ epigenetic target X with a known in vivoGI liability. The poster describes testing a limited set of reference compounds including drugs with a high (> 50%) and a low (0-4%) incidence of diarrhea in the clinic.

https://www.altisbiosystems.com/wp-content/uploads/2023/09/JNJ_poster1_SOT2023.pdf

Ready to design your study?

Talk to our team
Why GI Toxicity Slips Through Preclinical Screening

Why GI Toxicity Slips Through Preclinical Screening

Posted by
Ask a program lead which toxicity they are most afraid of finding late, and the gut is rarely the first…
Read More
Well-to-Well Consistency: Seeding, Confluence, and Real Signal vs Noise

Well-to-Well Consistency: Seeding, Confluence, and Real Signal vs Noise

Posted by
Some of the most damaging variability in a gut assay never involves the drug at all. It lives between neighboring…
Read More
Reproducibility in Your Hands: Why an Assay Drifts When It Moves Between Labs

Reproducibility in Your Hands: Why an Assay Drifts When It Moves Between Labs

Posted by
A model can be perfectly reproducible in the lab that built it and still fall apart the moment it lands…
Read More